Brian T Foley,
Los Alamos National Lab, Los Alamos, NM 87545
Send response to journal:
Re: Some history on work done by the Gallo and Montagnier groups, 1982-1985.
The Perth group wrote:
To claim an “infectious molecular clone of HIV-1”, the following must be done:
(a) Take the RNA from a particle which has the morphological
characteristics of retroviruses and which has been shown to be
(b) Introduce this RNA or its cDNA into cells;
(c) Show that the DNA is transcribed into the original RNA and that the RNA is translated into proteins;
(d) Show that the cells release particles morphologically identical to those from which the RNA was obtained;
(e) Show that the particles have the same RNA as the original RNA;
(f) Show that the particles are infectious.
Is this correct? If not, where are we wrong?
group is partially correct, but they obviously either do not understand
much about retrovirology and molecular genetics, or they understand but
wish to mislead others. I will attempt to explain some of their
(a) As far as
I know, it is not possible to use “molecular tweezers” of some type to
retrieve a single RNA molecule from a virus particle that has been
viewed under an electron microscope. There are many methods currently
available for cloning retroviral genomes that were not available in the
1983-1984 time period when the French lab team lead by Luc Montagnier
and the USA lab team lead by Robert Gallo were first characterizing
their isolates of HIV-1 M group subtype B virus. I will thus focus on
what these two groups did to come up with the first infectious
molecular clones of HIV.
HIV RNA, both groups used cell-free supernatant from HIV-infected
T-cells. Both groups first did extensive analyses to show that they
were able to culture and passage the virus on T-cells, and that the
cultured virus, even after many passages was still producing virions
which were strongly reactive with sera from AIDS pateints [2-26].
During this era before the first infectious molecular clone of the
virus was available it had already become clear that the cultured but
as-yet uncloned virus responsible for the AIDS epidemic in the USA and
Europe, and it was even linked to AIDS cases in Africa .
made extensive use of density gradient ultracentfifugation, often
retrieving the 1.16g/ml density band from one centrifugation and
loading it onto a second gradient to “double” band it. For one example,
the 1983 Barre-Sinoussi paper states that the virus could be propogated
on normal lymphocytes from ether newborns or adults, that the virus had
a buoyant density of 1.16 g/ml, and that identical cultures which had
not been infected with cell-free virus remained negative for RT
activity. They also state that they used methods which can distinguish
between true retroviral RT activity and a similar activity present in
DNA-dependent polymerases. RNA from this 1.16 g/ml band can be labeled
with 35S or 32P and used as a probe to locate
proviral genomes in genomic libraries or in cells infected with HIV or
related viruses [1,36 etc.].
(b) While it
is now possible to transfect cells with RNA or cDNA and observe the
effects of the transfected molecule, it is my understanding of the
history of this type of process, that such transfections were not yet
common in the 1984-1985 time period. Instead the cDNA was inserted into
a bacterial and/or mammalian cell cloning vector, prior to transfection
into the mammalian cells. See  for an example from a virus other
than a retrovirus.
transfection of cells with either complete viral cDNA, which can
potentially make full infectious virus particles, or cDNA derived from
spliced viral mRNAs which can make only some of the viral proteins but
not infectious particles, the viral RNA transcripts can be, and were
detected by Southern blotting and other methods. Likewise viral
proteins were detected by serology and other methods.
complete infectious molecular clones of HIV-1 are transfected into
cells, virus particles indistinguishable from those produced by other,
uncloned isolates of HIV-1 are indeed produced. These virus particles
produced from molecularly cloned HIV-1 genomes look identical to
uncloned viruses by electron microscopy ( see [12 and 28-33] for a few
examples). They react the same with sera from AIDS patients, but do not
react with sera from healthy controls nor controls infected with other
viruses [3,7, 40, etc…]. They produc proteins of the same molecular
weights as the protein produced by uncloned viruses of the same type.
They use the same cellular receptors for entry. Etc…
(e) Cloned an uncloned HIV-1 viruses do indeed contain the same 9.7 kb
genome, and produce the same genomic and spliced mRNA transcripts. It
is also critical to note that it has been shown many times, that
uninfected cells do not contain DNA or RNA sequences that hybridize to
HIV-1 probes. For example, figure 3 in  shows that no signal was
detected in uninfected H9 cells, HT cells or normal human thymus cells,
thus clearly indicating that the cloned virus was exogenous and not
some type of activated endogenous retrovirus. (f) Both cloned and
uncloned viral particles are infectious [37-40]. Mutations can be
introduced into the cloned viral genomes to reduce or eliminate this
infectivity [39, 41-43, etc…].
The Perth group wrote:
But where are the references that vindicate these [Brian Foley’s] claims?
Before the gene of the human insulin was cloned, a protein was isolated
(obtained separately from all other human proteins) and was shown to
have some specific properties. Subsequently, this protein was shown to
be coded by certain sequences in the DNA obtained from human cells.
Then the insulin gene was cloned. That is, when the DNA sequences were
introduced in suitable cells, the cells produced insulin.
Where are the
references that vindicate the Perth group’s claims? How was human
insulin “purified” to 100% purity, separate from all other human
proteins? See [34,35] for a start. I am not an expert on insulin, but I
believe that it was first studied in pigs and cows, and that the human
gene was most likely identified by Southern blotting with a pig or cow
insulin gene or cDNA. This would be analogous to identifying the HIV-1
genome by Southern blotting with a SIV genome or gene fragment, without
purifying or “isolating” the HIV virions. HIV was cloned and sequenced
before the first SIV was molecularly characterized. The only point I am
trying to make here is that the techniques of molecular biology,
whether they are applied to mammalian genes and proteins or viral genes
and proteins, are powerful and effective.
1: Alizon M, Sonigo P, Barre-Sinoussi F, Chermann JC, Tiollais P,
Montagnier L, Wain-Hobson S.
Molecular cloning of lymphadenopathy-associated virus.
Nature. 1984 Dec 20-1985 Jan 2;312(5996):757-60.
2: Sarngadharan MG, DeVico AL, Bruch L, Schupbach J, Gallo RC.
HTLV-III: the etiologic agent of AIDS.
Princess Takamatsu Symp. 1984;15:301-8.
3: Markham PD, Sarngadharan MG, Salahuddin SZ, Popovic M, Gallo RC.
Correlation between exposure to human T-cell leukemia-lymphoma
virus-III and the development of AIDS.
Ann N Y Acad Sci. 1984;437:106-9.
4: Popovic M, Sarngadharan MG, Read E, Gallo RC
Detection, isolation, and continuous production of cytopathic
retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.
Science. 1984 May 4;224(4648):497-500.
5: Gajdusek DC, Amyx HL, Gibbs CJ Jr, Asher DM, Yanagihara RT,
Rodgers-Johnson P, Brown PW, Sarin PS, Gallo RC Jr, Maluish A, et al.
Transmission experiments with human T-lymphotropic retroviruses and
human AIDS tissue.
Lancet. 1984 Jun 23;1(8391):1415-6.
6: Schupbach J, Sarngadharan MG, Gallo RC.
Antigens on HTLV-infected cells recognized by leukemia and AIDS
sera are related to HTLV viral glycoprotein.
Science. 1984 May 11;224(4649):607-10.
7: Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC.
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III)
in the serum of patients with AIDS.
Science. 1984 May 4;224(4648):506-8.
8: Schupbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG,
Serological analysis of a subgroup of human T-lymphotropic retroviruses
(HTLV-III) associated with AIDS.
Science. 1984 May 4;224(4648):503-5.
9: Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF,
Palker TJ, Redfield R, Oleske J, Safai B, et al.
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from
patients with AIDS and at risk for AIDS.
Science. 1984 May 4;224(4648):500-3.
10: Broder S, Gallo RC.
A pathogenic retrovirus (HTLV-III) linked to AIDS.
N Engl J Med. 1984 Nov 15;311(20):1292-7.
11: Chermann JC, Barre-Sinoussi F, Dauguet C, Brun-Vezinet F,
Rouzioux C, Rozenbaum W, Montagnier L.
Isolation of a new retrovirus in a patient at risk for acquired
Antibiot Chemother. 1983;32:48-53.
12: Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S,
Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C,
Rozenbaum W, Montagnier L.
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired
immune deficiency syndrome (AIDS).
Science. 1983 May 20;220(4599):868-71.
13: Chermann JC, Barre F, Montagnier L.
Retroviruses and acquired immunodeficiency syndrome (AIDS)
Bull Acad Natl Med. 1984 Jan-Feb;168(1-2):288-95.
14: Klatzmann D, Cavaille-Coll M, Brunet JB, Rozenbaum W,
Kernbaum S, Barre-Sinoussi F, Chermann JC, Montagnier L, Gluckman JC.
Immune status of AIDS patients in France: relationship with lymphadenopathy
associated virus tropism.
Ann N Y Acad Sci. 1984;437:228-37.
15: Montagnier L, Chermann JC, Barre-Sinoussi F, Klatzmann D,
Wain-Hobson S, Alizon M, Clavel F, Brun-Vezinet F, Vilmer E,
Rouzioux C, et al.
Lymphadenopathy associated virus and its etiological role in AIDS.
Princess Takamatsu Symp. 1984;15:319-31.
16: Montagnier L, Gruest J, Chamaret S, Dauguet C, Axler C, Guetard D,
Nugeyre MT, Barre-Sinoussi F, Chermann JC, Brunet JB, et al.
Adaptation of lymphadenopathy associated virus (LAV) to replication
in EBV-transformed B lymphoblastoid cell lines.
Science. 1984 Jul 6;225(4657):63-6.
17: Brun-Vezinet F, Rouzioux C, Barre-Sinoussi F, Klatzmann D,
Saimot AG, Rozenbaum W, Christol D, Gluckmann JC, Montagnier L,
Detection of IgG antibodies to lymphadenopathy-associated virus in patients
with AIDS or lymphadenopathy syndrome.
Lancet. 1984 Jun 9;1(8389):1253-6.
18: Rey MA, Spire B, Dormont D, Barre-Sinoussi F, Montagnier L,
Characterization of the RNA dependent DNA polymerase of a new
human T-lymphotropic retrovirus (lymphadenopathy associated virus).
Biochem Biophys Res Commun. 1984 May 31;121(1):126-33.
19: Papaevangelou G, Economidou J, Kallinikos J, Choreimi H, Mandalaki T,
Stratigos J, Geroldi D, Barre-Sinoussi F, Chermann JC, Montagnier L.
Lymphadenopathy associated virus in AIDS, lymphadenopathy associated
syndrome, and classic Kaposi patients in Greece.
Lancet. 1984 Sep 15;2(8403):642.
20: Vilmer E, Fischer A, Griscelli C, Barre-Sinoussi F, Vie V,
Chermann JC, Montagnier L, Rouzioux C, Brun-Vezinet F, Rosenbaum W.
Possible transmission of a human lymphotropic retrovirus (LAV) from mother to
infant with AIDS.
Lancet. 1984 Jul 28;2(8396):229-30.
21: Kalyanaraman VS, Cabradilla CD, Getchell JP, Narayanan R,
Braff EH, Chermann JC, Barre-Sinoussi F, Montagnier L, Spira TJ, Kaplan J, et al.
Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in
patients with AIDS.
Science. 1984 Jul 20;225(4659):321-3.
22: Melbye M, Biggar RJ, Chermann JC, Montagnier L, Stenbjerg S, Ebbesen P
High prevalence of lymphadenopathy virus (LAV) in European haemophiliacs.
Lancet. 1984 Jul 7;2(8393):40-1.
23: Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D,
Hercend T, Gluckman JC, Montagnier L.
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus
Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8.
24: Laurence J, Brun-Vezinet F, Schutzer SE, Rouzioux C, Klatzmann D,
Barre-Sinoussi F, Chermann JC, Montagnier L.
Lymphadenopathy-associated viral antibody in AIDS. Immune correlations
and definition of a carrier state.
N Engl J Med. 1984 Nov 15;311(20):1269-73.
25: Brun-Vezinet F, Rouzioux C, Montagnier L, Chamaret S, Gruest J,
Barre-Sinoussi F, Geroldi D, Chermann JC, McCormick J, Mitchell S, et al.
Prevalence of antibodies to lymphadenopathy-associated retrovirus in African
patients with AIDS.
Science. 1984 Oct 26;226(4673):453-6.
26: Spire B, Barre-Sinoussi F, Montagnier L, Chermann JC.
Inactivation of lymphadenopathy associated virus by chemical disinfectants.
Lancet. 1984 Oct 20;2(8408):899-901.
27: Omata T, Kohara M, Sakai Y, Kameda A, Imura N, Nomoto A
Cloned infectious complementary DNA of the poliovirus Sabin 1 genome:
biochemical and biological properties of the recovered virus.
Gene. 1984 Dec;32(1-2):1-10.
28 : Casareale D, Sinangil F, Hedeskog M, Ward W, Volsky DJ, Sonnabend J.
Establishment of retrovirus-, Epstein-Barr virus-positive B-lymphoblastoid cell
lines derived from individuals at risk for acquired immune deficiency syndrome
AIDS Res. 1983-84;1(4):253-70.
29: Markham PD, Shaw GM, Salahuddin SZ, Hahn B, Sarngadharan MG,
Etiology of AIDS: biological and biochemical characteristics of HTLV-III.
Adv Exp Med Biol. 1985;187:13-34.
30: Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E,
Griscelli C, Brun-Veziret F, Rouzioux C, Gluckman JC, Chermann JC, et al.
Selective tropism of lymphadenopathy associated virus (LAV) for
helper-inducer T lymphocytes.
Science. 1984 Jul 6;225(4657):59-63.
31: Epstein LG, Sharer LR, Cho ES, Myenhofer M, Navia B, Price RW
HTLV-III/LAV-like retrovirus particles in the brains of patients with
AIDS Res. 1984-85;1(6):447-54.
32: Naito M, Jogasaki M, Takahashi K, Matsumi S, Hattori T, Takatsuki K.
Ultrastructural behavior of human immunodeficiency virus (HIV) in
multinucleated giant cells in the brain of a Japanese hemophiliac presenting
Ultrastruct Pathol. 1989 Jul-Aug;13(4):433-41.
33: Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH.
Molecular characterization of human immunodeficiency virus type 1 cloned
directly from uncultured human brain tissue: identification of
replication-competent and -defective viral genomes.
J Virol. 1991 Aug;65(8):3973-85.
34: Villa-Komaroff L, Efstratiadis A, Broome S, Lomedico P, Tizard R,
Naber SP, Chick WL, Gilbert W.
A bacterial clone synthesizing proinsulin.
Proc Natl Acad Sci U S A. 1978 Aug;75(8):3727-31.
35: : Nolan C, Margoliash E, Peterson JD, Steiner DF.
The structure of bovine proinsulin.
J Biol Chem. 1971 May 10;246(9):2780-95.
36: Hahn BH, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-Staal F.
Molecular cloning and characterization of the HTLV-III virus associated
Nature. 1984 Nov 8-14;312(5990):166-9.
37: Fisher AG, Collalti E, Ratner L, Gallo RC, Wong-Staal F.
A molecular clone of HTLV-III with biological activity.
Nature. 1985 Jul 18-24;316(6025):262-5.
38: : Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME, Broder S,
Gallo RC, Wong-Staal F.
Infectious mutants of HTLV-III with changes in the 3' region and markedly
reduced cytopathic effects.
Science. 1986 Aug 8;233(4764):655-9.
39: Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM,
Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC, et al.
The trans-activator gene of HTLV-III is essential for virus replication.
Nature. 1986 Mar 27-Apr 2;320(6060):367-71.
40: Chang NT, Chanda PK, Barone AD, McKinney S, Rhodes DP,
Tam SH, Shearman CW, Huang J, Chang TW, Gallo RC, et al.
Expression in Escherichia coli of open reading frame gene segments of
Science. 1985 Apr 5;228(4695):93-6.
41: Valsamakis A, Zeichner S, Carswell S, Alwine JC.
The human immunodeficiency virus type 1 polyadenylylation signal:
a 3' long terminal repeat element upstream of the AAUAAA necessary for
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2108-12.
42: Julias JG, Boyer PL, McWilliams MJ, Alvord WG, Hughes SH.
Mutations at position 184 of human immunodeficiency virus type-1 reverse
transcriptase affect virus titer and viral DNA synthesis.
Virology. 2004 Apr 25;322(1):13-21.
43: Dubay JW, Roberts SJ, Brody B, Hunter E.
Mutations in the leucine zipper of the human immunodeficiency
virus type 1 transmembrane glycoprotein affect fusion and infectivity.
J Virol. 1992 Aug;66(8):4748-56.